BACKGROUND: High-dose busulfan is widely used as part of conditioning regimens for patients who are undergoing hematopoietic stem cell or bone marrow transplantation. High plasma concentrations of busulfan have been linked to the occurrence of hepatic venoocclusive disease (VOD), a severe complication associated with a high mortality. Because conjugation with glutathione, the major route of biotransformation of busulfan, is predominantly catalyzed by the isozyme glutathione S-transferase A1 (GSTA1), we hypothesized that low expression or function of GSTA1 in liver caused by genetic polymorphisms may be the mechanism underlying VOD. METHODS: Immunoblot analysis of GSTA and measurement of busulfan-glutathione conjugation by liquid chromatography-mass spectrometry were performed in 48 normal human liver samples. To search for polymorphisms, the complete GSTA1 coding regions and the promoter fragment were sequenced. All results were compared by multivariate analysis. RESULTS: Absolute levels of GSTA protein and formation rates of busulfan-glutathione conjugate displayed a 7- and 8-fold range, from 240 to 1600 pmol/mg and 25 to 205 pmol/min per milligram of total cytosolic protein, respectively, and correlate (r2 = 0.49, P <.0001). A total of 8 single nucleotide polymorphisms (SNPs) of GSTA1 were identified, 1 of which was a silent mutation in exon 5 (A375G); all others were found in the promoter region. Haplotype analysis revealed the existence of 5 defined alleles. There was no significant relationship between any of the GSTA1 SNPs or haplotypes and either hepatic glutathione S-transferase A (GSTA) expression or GSTA1 function. CONCLUSIONS: The identified GSTA1 polymorphisms are not likely to be related to the VOD because they do not appear to be associated with changes in GSTA expression or function. Compared with other members of the GST family, GSTA1 displays surprisingly little variation.
BACKGROUND: High-dose busulfan is widely used as part of conditioning regimens for patients who are undergoing hematopoietic stem cell or bone marrow transplantation. High plasma concentrations of busulfan have been linked to the occurrence of hepatic venoocclusive disease (VOD), a severe complication associated with a high mortality. Because conjugation with glutathione, the major route of biotransformation of busulfan, is predominantly catalyzed by the isozyme glutathione S-transferase A1 (GSTA1), we hypothesized that low expression or function of GSTA1 in liver caused by genetic polymorphisms may be the mechanism underlying VOD. METHODS: Immunoblot analysis of GSTA and measurement of busulfan-glutathione conjugation by liquid chromatography-mass spectrometry were performed in 48 normal human liver samples. To search for polymorphisms, the complete GSTA1 coding regions and the promoter fragment were sequenced. All results were compared by multivariate analysis. RESULTS: Absolute levels of GSTA protein and formation rates of busulfan-glutathione conjugate displayed a 7- and 8-fold range, from 240 to 1600 pmol/mg and 25 to 205 pmol/min per milligram of total cytosolic protein, respectively, and correlate (r2 = 0.49, P <.0001). A total of 8 single nucleotide polymorphisms (SNPs) of GSTA1 were identified, 1 of which was a silent mutation in exon 5 (A375G); all others were found in the promoter region. Haplotype analysis revealed the existence of 5 defined alleles. There was no significant relationship between any of the GSTA1 SNPs or haplotypes and either hepatic glutathione S-transferase A (GSTA) expression or GSTA1 function. CONCLUSIONS: The identified GSTA1 polymorphisms are not likely to be related to the VOD because they do not appear to be associated with changes in GSTA expression or function. Compared with other members of the GST family, GSTA1 displays surprisingly little variation.
Authors: Kana Mizuno; Min Dong; Tsuyoshi Fukuda; Sharat Chandra; Parinda A Mehta; Scott McConnell; Elias J Anaissie; Alexander A Vinks Journal: Clin Pharmacokinet Date: 2018-05 Impact factor: 6.447
Authors: Nissa Abbasi; Barbara Vadnais; Jennifer A Knutson; David K Blough; Edward J Kelly; Paul V O'Donnell; H Joachim Deeg; Matthew A Pawlikowski; Rodney J-Y Ho; Jeannine S McCune Journal: J Clin Pharmacol Date: 2010-12-06 Impact factor: 3.126
Authors: Christoph A Ritter; Bernhard Sperker; Markus Grube; Dana Dressel; Christiane Kunert-Keil; Heyo K Kroemer Journal: Br J Pharmacol Date: 2002-12 Impact factor: 8.739
Authors: Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema Journal: Br J Clin Pharmacol Date: 2008-11-17 Impact factor: 4.335
Authors: A Nagler; M Labopin; R Berger; D Bunjes; A Campos; G Socié; N Kröger; H Goker; I Yakoub-Agha; A Shimoni; M Mohty; V Rocha Journal: Bone Marrow Transplant Date: 2014-02-17 Impact factor: 5.483
Authors: Kathryn L Bradford; Siyu Liu; Maja Krajinovic; Marc Ansari; Elizabeth Garabedian; John Tse; Xiaoyan Wang; Kit L Shaw; H Bobby Gaspar; Fabio Candotti; Donald B Kohn Journal: Biol Blood Marrow Transplant Date: 2020-07-09 Impact factor: 5.742
Authors: Angela Roco; Luis Quiñones; José A G Agúndez; Elena García-Martín; Valentina Squicciarini; Carla Miranda; Joselyn Garay; Nancy Farfán; Iván Saavedra; Dante Cáceres; Carol Ibarra; Nelson Varela Journal: Front Genet Date: 2012-11-02 Impact factor: 4.599